Akouos is a biotechnology company developing gene therapies to restore, preserve, and protect hearing, primarily targeting genetically defined patient populations with inner ear disorders.[1][2][3] It builds AAV-based gene therapies, such as AK-OTOF for otoferlin (OTOF)-mediated hearing loss and AK-CLRN1 for Usher syndrome, administered via intracochlear injection to deliver functional genes to inner ear cells.[3][6] These address unmet needs in hearing loss affecting millions, including congenital forms from single-gene mutations, serving patients with conditions like acute sensorineural hearing loss and balance disorders.[1][3][4] Now a subsidiary of Eli Lilly and Company and headquartered in Boston, Akouos shows growth through clinical advancement—AK-OTOF in Phase 2—and partnerships, though it has not yet achieved regulatory approval.[3][6]
Akouos was founded in 2016 (with launch in 2017) by Dr. Manny Simons, a neuroscientist with a Harvard neuroscience degree, MIT PhD in biomedical engineering, and Harvard MBA, motivated by personal passion for music and awareness of hearing's importance.[2][4] Simons, as CEO, aimed to pioneer inner ear gene therapies using ancestral AAV (Anc-AAV) vectors, starting with Anc80 for superior inner ear gene expression.[2] The company emerged from breakthroughs in AAV technology via partnerships with Massachusetts Eye and Ear (experts in hearing science) and Lonza (AAV manufacturing), securing exclusive licenses for hearing and balance disorders.[2] Backed by 5AM Ventures, NEA, and Partners Innovation Fund, early traction included preclinical validation in non-human primates and a focus on precision genetic medicines.[2][5]
Akouos rides the gene therapy wave in precision medicine, targeting the growing hearing loss market—impacting 300,000+ Americans with genetic forms alone—amid advances in AAV vectors and inner ear delivery.[1][4] Timing aligns with maturing biotech tools post-2017 launches, filling gaps where no gene therapies exist for hearing, a field dominated by devices like cochlear implants.[2][4] Market forces favor it: rising genetic diagnostics, aging populations driving ototoxicity/noise-related loss, and Big Pharma interest (e.g., Eli Lilly acquisition), enabling scaled clinical trials.[3] It influences the ecosystem by validating inner ear gene delivery, potentially inspiring therapies for neurotology and balance, while contributing to Massachusetts' biotech hub.[1][2]
Akouos is poised for milestones like Phase 2 data from AK-OTOF (targeting OTOF-mediated loss) and ongoing trials starting in 2024-2025 for broader indications, potentially yielding first approvals in genetically defined hearing disorders.[3][6] Trends like refined AAV engineering, expanded genetic screening, and combo therapies (e.g., with regeneration) will shape its path, amplified by Lilly's resources for global reach.[3] Its influence may evolve from pioneer to category leader, transforming hearing from symptomatic management to curative, ultimately making "healthy hearing available to all" as envisioned at founding.[2]
Akouos has raised $168.0M in total across 3 funding rounds.
Akouos's investors include 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Deerfield Management, Endeavor Venture Funds, Frazier Healthcare Partners, New Enterprise Associates, Nextech Invest, OrbiMed, RA Capital, RiverVest.
Akouos has raised $168.0M across 3 funding rounds. Most recently, it raised $110.0M Series B in March 2020.
